💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Somatrem

CHEMBL1201620 Phase 4 معتمد Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
1009.1 g/mol
LogP
-6.4
Phase
4

Somatrem is a recombinant human growth hormone preparation that includes an additional methionine residue at the N-terminus compared to native pituitary-derived GH, used to treat growth failure due to growth hormone deficiency in children. Like endogenous GH, it binds to GH receptors to stimulate IGF-1 production, linear bone growth, and protein anabolism. It has largely been replaced by somatropin, which has the identical amino acid sequence to native human GH.

الوزن الجزيئي

1009,1000 g/mol

LogP

-6,40

TPSA

452,00 Ų

قاعدة ليبينسكي للخمسة

راسب

آلية العمل

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

SMILES

C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@H](C(C)C)N

InChI

InChI=1S/C43H72N14O14/c1-21(2)33(44)40(69)51-23(5)36(65)55-34(22(3)4)41(70)49-19-29(58)52-25(12-14-31(60)61)37(66)54-26(13-15-32(62)63)42(71)57-18-8-10-27(57)38(67)50-20-30(59)56-17-7-11-28(56)39(68)53-24(35(45)64)9-6-16-48-43(46)47/h21-28,33-34H,6-20,44H2,1-5H3,(H2,45,64)(H,49,70)(H,50,67)(H,51,69)(H,52,58)(H,53,68)(H,54,66)(H,55,65)(H,60,61)(H,62,63)(H4,46,47,48)/t23-,24-,25-,26-,27-,28-,33-,34-/m0/s1

Molecular Formula

C43H72N14O14

HBD / HBA

13 / 16

الروابط القابلة للدوران

29

الذرات الثقيلة

71

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

Somatrem is a recombinant human growth hormone preparation that includes an additional methionine residue at the N-terminus compared to native pituitary-derived GH, used to treat growth failure due to growth hormone deficiency in children. Like endogenous GH, it binds to GH receptors to stimulate IGF-1 production, linear bone growth, and protein anabolism. It has largely been replaced by somatropin, which has the identical amino acid sequence to native human GH.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Somatrem is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201620. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5487805. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.